T Cell Receptor Immunotherapy Targeting MAGE-A3
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for T Cell Receptor Immunotherapy Targeting MAGE-A3, covering 2019-06-05 to 2022-03-29. Get the full timeline:
Most recent: Clinical Trial Update: T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive [Phase 1, Phase 2]